SEC Form 4 · accession 0001104659-26-077305
RHYTHM PHARMACEUTICALS, INC. · RYTM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lynn A. Tetrault
Director
Period of report
Jun 22, 2026
Accepted (ET)
Jun 24, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001649904
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 22, 2026 | M | 37,000 | $28.27 | A | 44,000 | D | |
| Common StockF2 | Jun 22, 2026 | S | 37,000 | $100.3215 | D | 7,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $28.27 | Jun 22, 2026 | M | 37,000 | D | — | Dec 8, 2030 | Common Stock | 37,000 | 0 | D |
Explanation of responses
- F1The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on December 15, 2025.
- F2The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $100.00 to $100.91. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F3The option is fully vested and exercisable.